Agile Therapeutics to Present at Biotech 2012

PRINCETON, NJ--(Marketwire - Oct 22, 2012) - Agile Therapeutics announced today that Al Altomari, President and Chief Executive Officer, will be presenting at Biotech 2012. The event takes place October 22, 2012 in Philadelphia.

Mr. Altomari will be participating in the CEO panel discussion: "Lather, Rinse, Repeat," which will focus on the challenges of starting, running, and selling a life sciences company and cover issues such as obtaining funding, building the best team, and the importance of establishing a meaningful company culture. Mr. Altomari will bring insights from his experience with Barrier Therapeutics, Johnson & Johnson, and Ortho-McNeil Pharmaceuticals, as well as his current work with Agile Therapeutics, where he has led the company through rounds of funding as it moves through the final stages of development of commercialization of its investigational once-weekly contraceptive patch, AG200-15, which is designed to deliver a low daily estrogen dose.

"I am greatly looking forward to participating in Biotech 2012," said Mr. Altomari. "Having been through the process of building life sciences companies from the ground up, sometimes in challenging economic circumstances, as in the case of Agile Therapeutics, I feel that I can share valuable insights on the process. I look forward to a productive and dynamic discussion."

Agile recently filed the NDA for AG200-15 and anticipates a response in the first quarter of 2013.

About AG200-15
AG200-15 is an investigational combination hormonal contraceptive patch, designed to deliver a low dose of ethinyl estradiol comparable to low-dose combination oral contraceptives. The phase III trials for AG200-15 enrolled nearly 2,000 women and formed the basis for the Company's application to the US Food and Drug Administration in 2012.

The AG200-15 patch is intended to be applied once weekly for three weeks, followed by a fourth, patch-free week. The patch is designed using a soft, flexible cloth, with a silky feel, and is intended to provide excellent adhesion, comfort, and appearance.

About Agile Therapeutics
Agile Therapeutics is a pharmaceutical development company specializing in Women's Healthcare products, with an initial focus on providing women with more options and potentially more convenient methods of hormonal contraception. The company's lead investigational product, AG200-15, is designed to be a once-weekly contraceptive patch that has recently been submitted to the FDA as a New Drug Application (NDA) for review. In addition, Agile is also developing a low dose, progestin-only contraceptive patch, AG890 (formerly AG900). Both AG200-15 and AG890 incorporate proprietary transdermal delivery technology, Skinfusion®, developed by Agile, consisting of an active and peripheral adhesive system that has been designed to allow stable drug delivery and dependable adhesion over seven days. For more information, please visit http://www.agiletherapeutics.com.

About Biotech 2012
BioNJ and Pennsylvania Bio are pleased to present the 12th Annual Biotech Symposium, taking place October 22, 2012 in Philadelphia, PA. Biotech 2012: Find. Fund. Facilitate is the foremost bioscience conference in the Mid-Atlantic region, bringing together top bioscience leaders from around the world to network, connect with potential partners, share business strategies, and learn from their peers.

This year's conference will take place in one day, combining all of the most popular elements of our past agendas into a targeted program designed to advance the growth and development of the bioscience industry in our region. Attendees will have opportunities for information sharing, new skill development, networking, collaboration, and partnering among companies at all stages of growth.

This must-attend event will feature thought-provoking panel discussions, dynamic plenary sessions, renowned keynote speakers, company showcase, Partnering sessions, an Innovation Corridor, exhibiting, and much more.